Patents by Inventor Jean-Pierre Sommadossi

Jean-Pierre Sommadossi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY
    Publication number: 20240148770
    Abstract: A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g.
    Type: Application
    Filed: December 14, 2023
    Publication date: May 9, 2024
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa, Keith M. Pietropaolo, Xiao-Jian Zhou
  • 2?-substituted-N-substituted purine nucleotides for RNA virus treatment
    Patent number: 11975016
    Abstract: The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: May 7, 2024
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS
    Publication number: 20240018179
    Abstract: A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
    Type: Application
    Filed: January 23, 2023
    Publication date: January 18, 2024
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Adel Moussa, Jean-Pierre Sommadossi
  • BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
    Publication number: 20240002426
    Abstract: A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
    Type: Application
    Filed: January 23, 2023
    Publication date: January 4, 2024
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY
    Publication number: 20230364121
    Abstract: Methods of treatment and prevention and assays to select optimal compounds for treating or preventing infections from severe acute respiratory syndrome (SARS)-related coronaviruses (SARS-CoV), such as SARS-CoV-2, that interfere with the activity of the nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12). The invention establishes for the first time herein the foundational discovery of the mechanism of action of the NiRAN-domain, and how it can be used in pharmaceutical therapy against SARS-CoV infection, including a SARS-CoV-2 infection, or exposure.
    Type: Application
    Filed: April 7, 2023
    Publication date: November 16, 2023
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Kai Lin, Adel Moussa, Bruno Canard, Ashleigh Shannon
  • Highly active compounds against COVID-19
    Patent number: 11813278
    Abstract: The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: November 14, 2023
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Highly active compounds against COVID-19
    Patent number: 11738038
    Abstract: The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: August 29, 2023
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Highly active compounds against COVID-19
    Patent number: 11707480
    Abstract: The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: July 25, 2023
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Treatment of HCV infected patients with cirrhosis
    Patent number: 11690860
    Abstract: A pharmaceutical composition that includes a compound of the structure: to treat an HCV infected patient with cirrhosis, and uses thereof.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: July 4, 2023
    Assignee: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa, Keith M. Pietropaolo, Xiao-Jian Zhou
  • CRYSTALLINE EPINEPHRINE MALONATE SALT
    Publication number: 20230086578
    Abstract: Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.
    Type: Application
    Filed: November 18, 2022
    Publication date: March 23, 2023
    Applicant: Biothea Pharma, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT
    Publication number: 20230017958
    Abstract: The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.
    Type: Application
    Filed: September 22, 2021
    Publication date: January 19, 2023
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Crystalline epinephrine malonate salt
    Patent number: 11505521
    Abstract: Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: November 22, 2022
    Assignee: Biothea Pharma, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19
    Publication number: 20220347200
    Abstract: The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
    Type: Application
    Filed: May 3, 2021
    Publication date: November 3, 2022
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19
    Publication number: 20220347199
    Abstract: The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
    Type: Application
    Filed: February 24, 2021
    Publication date: November 3, 2022
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
    Publication number: 20220267366
    Abstract: A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 25, 2022
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19
    Publication number: 20210275563
    Abstract: The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.
    Type: Application
    Filed: November 10, 2020
    Publication date: September 9, 2021
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS
    Publication number: 20210277045
    Abstract: A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
    Type: Application
    Filed: May 3, 2021
    Publication date: September 9, 2021
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Adel Moussa, Jean-Pierre Sommadossi
  • CRYSTALLINE EPINEPHRINE MALONATE SALT
    Publication number: 20210214301
    Abstract: Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 15, 2021
    Applicant: Biothea Pharma, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Crystalline epinephrine malonate salt
    Patent number: 10995059
    Abstract: Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: May 4, 2021
    Assignee: Biothea Pharma, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS
    Publication number: 20210087217
    Abstract: A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
    Type: Application
    Filed: December 10, 2020
    Publication date: March 25, 2021
    Applicant: Atea Pharmaceuticals, Inc.
    Inventors: Adel Moussa, Jean-Pierre Sommadossi